Alvotech(US:ALVO) Globenewswire·2026-03-18 22:15Core Insights - Alvotech reported total revenues of $593 million for FY 2025, reflecting a 21% year-on-year increase [3] - The company has launched three newly approved biosimilars and has a pipeline of 30 biosimilars in development [5][6] - Alvotech anticipates total revenues of $650-700 million for 2026, with adjusted EBITDA expected to rise to $180-220 million [11] Financial Performance - Total revenues for Q4 2025 were $173 million, a 13% increase year-on-year [7] - Adjusted EBITDA for FY 2025 was $137 million, up 27% year-on-year, with a gross margin of 61% [7] - The cash balance as of December 31, 2025, was $172 million [7] Product Development and Approvals - Alvotech has five approved biosimilars on the market, including products referencing Humira®, Stelara®, and Simponi® [18] - Recent approvals include AVT05 as a biosimilar to Simponi® and AVT03 as a biosimilar to Prolia® and Xgeva® in the EEA [7] - The company expects to receive U.S. approval for four Biologics License Applications by late 2026 [12] Strategic Initiatives - Alvotech raised nearly $300 million from capital markets to support its development programs and manufacturing platform [6] - The company has expanded its global reach through new commercial partnerships and acquisitions, including the R&D organization of Xbrane in Sweden [6][7] - Leadership changes include the appointment of Lisa Graver as Chief Executive Officer and other key management roles [10] Market Outlook - Management reaffirms its outlook for 2026, focusing on cash flow and margin expansion [11] - The anticipated revenue range for 2026 reflects continued double-digit sales growth [11] - The company is addressing regulatory observations from the FDA inspection of its Reykjavik manufacturing facility and plans to resubmit applications in Q2 2026 [9]